Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: A meta-analysis

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 136-144

  Huang, Xiao ^a   Zhao, Jiangpei ^b   Zhao, Tongfeng ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b Hangzhou Hospital of Traditional Chinese Medicine   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Blood lipids; Meta analysis; Peroxisome proliferator activated receptor gamma 2; Polymorphism

Indexed keywords

ALANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; TRIACYLGLYCEROL;

ALLELE; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AMINO ACID SUBSTITUTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; HUMANS; LIPIDS; MALE; POLYMORPHISM, GENETIC; PPAR GAMMA; TRIGLYCERIDES;

EID: 79952195259     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.043     Document Type: Article

References (89)

1. Aslam F., Haque A., Lee L.V., Foody J. Hyperlipidemia in older adults. Clin Geriatr Med 2009, 4:591-606.
2. Hegele R.A. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009, 2:109-121.
3. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 7307:707-713.
4. Ringel J., Engeli S., Distler A., Sharma A.M. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999, 2:450-453.
5. Stefanski A., Majkowska L., Ciechanowicz A., et al. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 2006, 6:736-743.
6. González Sánchez J.L., Serrano Ríos M., Fernández Perez C., Laakso M., Martínez Larrad M.T. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002, 4:495-501.
7. Eurlings P.M., van der Kallen C.J., Vermeulen V.M., de Bruin T.W. Variants in the PPARgamma gene affect fatty acid and glycerol metabolism in familial combined hyperlipidemia. Mol Genet Metab 2003, 3:296-301.
8. Beamer B.A., Yen C.J., Andersen R.E., et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998, 11:1806-1808.
9. Srámková D., Kunesová M., Hainer V., et al. Is a Pro12Ala polymorphism of the PPARgamma2 gene related to obesity and type 2 diabetes mellitus in the Czech population?. Ann N Y Acad Sci 2002, 967:265-273.
10. Frederiksen L., Brødbaek K., Fenger M., et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002, 8:3989-3992.
11. Rosmond R., Chagnon M., Bouchard C. The Pro12Ala PPARgamma2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab Res Rev 2003, 2:159-163.
12. Chistiakov D.A., Potapov V.A., Khodirev D.S., et al. The PPARgamma Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects. Diab Vasc Dis Res 2010, 1:56-62.
13. Regieli J.J., Jukema J.W., Doevendans P.A., et al. PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients. Diabetes Care 2009, 5:839-844.
14. Evangelisti L., Attanasio M., Lucarini L., et al. PPARgamma promoter polymorphisms and acute coronary syndrome. Atherosclerosis 2009, 1:186-191.
15. Montagnana M., Fava C., Nilsson P.M., et al. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals. Diabet Med 2008, 8:902-908.
16. Zafarmand M.H., van der Schouw Y.T., Grobbee D.E., de Leeuw P.W., Bots M.L. Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manage 2008, 2:427-436.
17. Jorsal A., Tarnow L., Lajer M., et al. The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol Genet Metab 2008, 3:347-351.
18. Morini E., Tassi V., Capponi D., et al. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity (Silver Spring) 2008, 6:1467-1470.
19. Bendlová B., Vejrazková D., Vcelák J., et al. PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2. Physiol Res 2008, 1(Suppl):S77-S90.
20. Helwig U., Rubin D., Kiosz J., et al. The minor allele of the PPARgamma2 pro12Ala polymorphism is associated with lower postprandial TAG and insulin levels in non-obese healthy men. Br J Nutr 2007, 5:847-854.
21. Vaccaro O., Lapice E., Monticelli A., et al. Pro12Ala polymorphism of the PPARgamma2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients. Diabetes Care 2007, 5:1156-1161.
22. Yaffe K., Kanaya A.M., Lindquist K., et al. PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol Aging 2008, 1:78-83.
23. Cardona F., Morcillo S., Gonzalo-Marín M., et al. Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin Chem 2006, 10:1920-1925.
24. Swarbrick M.M., Chapman C.M., McQuillan B.M., et al. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001, 3:277-282.
25. Douglas J.A., Erdos M.R., Watanabe R.M., et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 2001, 4:886-890.
26. Eriksson J.G., Lindi V., Uusitupa M., et al. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 2002, 7:2321-2324.
27. Simón I., Vendrell J., Gutiérrez C., et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res 2002, 3:143-149.
28. Ahluwalia M., Evans M., Morris K., et al. The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naïve patients with type 2 diabetes. Diabetes Obes Metab 2002, 6:376-378.
29. Blüher M., Lübben G., Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003, 3:825-831.
30. Lindi V., Schwab U., Louheranta A., et al. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab 2003, 1:52-60.
31. Ostgren C.J., Lindblad U., Melander O., et al. Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project. J Hypertens 2003, 9:1657-1662.
32. Buzzetti R., Petrone A., Ribaudo M.C., et al. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 2004, 12:1050-1054.
33. Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., et al. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 2004, 9:4238-4242.
34. Barbieri M., Rizzo M.R., Papa M., et al. Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors. Exp Gerontol 2005, 7:599-604.
35. Fornage M., Jacobs D.R., Steffes M.W., et al. Inverse effects of the PPAR(gamma)2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and whites. The CARDIA study. Metabolism 2005, 7:910-917.
36. Tavares V., Hirata R.D., Rodrigues A.C., et al. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes Metab 2005, 5:605-611.
37. De Cosmo S., Motterlini N., Prudente S., et al. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009, 12:2920-2929.
38. Meirhaeghe A., Fajas L., Helbecque N., et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000, 2:195-199.
39. Pintérová D., Cerná M., Kolostová K., et al. The frequency of alleles of the Pro12Ala polymorphism in PPARgamma2 is different between healthy controls and patients with type 2 diabetes. Folia Biol (Praha) 2004, 5:153-156.
40. Schäffler A., Barth N., Schmitz G., et al. Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine 2001, 3:369-373.
41. Milewicz A., Tworowska-Bardziñska U., Dunajska K., Jêdrzejuk D., Lwow F. Relationship of PPARgamma2 polymorphism with obesity and metabolic syndrome in postmenopausal Polish women. Exp Clin Endocrinol Diabetes 2009, 10:628-632.
42. Zietz B., Barth N., Spiegel D., et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp Clin Endocrinol Diabetes 2002, 2:60-66.
43. Aberle J., Hopfer I., Beil F.U., Seedorf U. Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 2006, 12:1709-1713.
44. Deeb S.S., Fajas L., Nemoto M., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 3:284-287.
45. Lu Z., Dong B., Mo X., et al. Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians. Exp Gerontol 2008, 12:1108-1113.
46. Hsieh M.C., Lin K.D., Tien K.J., et al. Common polymorphisms of the peroxisome proliferator-activated receptor- gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010, 8:1139-1144.
47. Li L.L., Ma X.L., Ran J.X., et al. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects. Clin Exp Pharmacol Physiol 2008, 2:187-191.
48. Hamada T., Kotani K., Tsuzaki K., et al. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. Metabolism 2007, 10:1345-1349.
49. Rhee E.J., Kwon C.H., Lee W.Y., et al. No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects. Circ J 2007, 3:338-342.
50. Mori Y., Kim-Motoyama H., Katakura T., et al. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998, 1:195-198.
51. Hara K., Okada T., Tobe K., et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000, 1:212-216.
52. Oh E.Y., Min K.M., Chung J.H., et al. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000, 5:1801-1804.
53. Yamamoto Y., Hirose H., Miyashita K., et al. PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 2002, 11:1407-1409.
54. Kahara T., Takamura T., Hayakawa T., et al. PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 2003, 2:209-212.
55. Iwata E., Yamamoto I., Motomura T., et al. The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese. Diabetes Res Clin Pract 2003, 1:55-59.
56. Kim K.S., Choi S.M., Shin S.U., Yang H.S., Yoon Y. Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 2004, 12:1538-1543.
57. Kang E.S., Park S.Y., Kim H.J., et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005, 2:202-208.
58. Moon M.K., Cho Y.M., Jung H.S., et al. Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and obesity in the Korean population. Diabet Med 2005, 9:1161-1166.
59. Rhee E.J., Oh K.W., Lee W.Y., et al. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch Med Res 2006, 1:86-94.
60. Liu L., Zheng T., Wang F., et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010, 1:144-149.
61. Yamamoto J., Kageyama S., Nemoto M., et al. PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients. Hypertens Res 2002, 1:25-29.
62. Li L., Cheng L.X., Nsenga R., He M.A., Wu T.C. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 2006, 7:300-304.
63. Mori H., Ikegami H., Kawaguchi Y., et al. The Pro12Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001, 4:891-894.
64. Yao Q., Nordfors L., Axelsson J., et al. Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 2005, 1:105-111.
65. Dongxia L., Qi H., Lisong L., Jincheng G. Association of peroxisome proliferator-activated receptor gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ J 2008, 4:551-557.
66. Caramori M.L., Canani L.H., Costa L.A., Gross J.L. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003, 12:3010-3013.
67. Tai E.S., Corella D., Deurenberg-Yap M., et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004, 4:674-685.
68. Andrulionytè L., Zacharova J., Chiasson J.L., Laakso M. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004, 12:2176-2184. STOP-NIDDM Study Group.
69. Pischon T., Pai J.K., Manson J.E., et al. Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol 2005, 8:1654-1658.
70. Ereqat S., Nasereddin A., Azmi K., Abdeen Z., Amin R. Impact of the Pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the palestinian type 2 diabetic patients. PPAR Res 2009, 2009:874126.
71. Haseeb A., Iliyas M., Chakrabarti S., et al. Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population. J Biosci 2009, 3:405-414.
72. Ben Ali S., Ben Yahia F., Sediri Y., et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem 2009, 16-17:1642-1647.
73. Ramírez-Salazar M., Pérez-Luque E., Fajardo-Araujo M., Garza S.M., Malacara J.M. Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women. Menopause 2008, 6:1151-1156.
74. Radha V., Vimaleswaran K.S., Babu S., et al. Lack of association between serum adiponectin levels and the Pro12Ala polymorphism in Asian Indians. Diabet Med 2007, 4:398-402.
75. Danawati C.W., Nagata M., Moriyama H., et al. A possible association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 gene with obesity in native Javanese in Indonesia. Diabetes Metab Res Rev 2005, 5:465-469.
76. Zouari Bouassida K., Chouchane L., Jellouli K., et al. The peroxisome proliferator activated receptorgamma2 (PPARgamma2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients. Diabetes Metab 2005, 2:119-123.
77. Mirzaei H., Akrami S.M., Golmohammadi T., et al. Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects. Metab Syndr Relat Disord 2009, 5:453-458.
78. Meshkani R., Taghikhani M., Larijani B., et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Clin Chem Lab Med 2007, 4:477-482.
79. Berman N.G., Parker R.A. Meta-analysis: neither quick nor easy. BMC Med Res Methodol 2002, 2:10.
80. Welton N.J., Caldwell D.M., Adamopoulos E., Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 2009, 9:1158-1165.
81. Fleiss J.L. The statistical basis of meta-analysis. Stat Methods Med Res 1993, 2:121-145.
82. Bax L., Yu L.M., Ikeda N., Tsuruta H., Moons K.G.M. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006, 6:50.
83. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7, (2008) []. http://mix-for-meta-analysis.info/.
84. Egger M., Davey Smith G., Schneider M., Minder C Bias in meta-analysis detected by a simples graphical test. BMJ 1997, 315:629-634.
85. Stojanovska L., Honisett S.Y., Komesaroff P.A. The anti-atherogenic effects of thiazolidinediones. Curr Diabetes Rev 2007, 1:67-74.
86. Zhao T., Nzekebaloudou M., Lv J. Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis. Atherosclerosis 2010, 2:461-467.
87. Thakkinstian A., McElduff P., D'Este C., Duffy D., Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005, 9:1291-1306.
88. Huguenin G.V., Rosa G. The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr 2010, 4:488-497.
89. Furuhashi M., Ura N., Nakata T., Shimamoto K. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care 2003, 2:471-474.